AARD
Aardvark Therapeutics, Inc.
Key Financials
Operating Income
$-62725000
↓ 175.3%
EPS (Diluted)
$-2.93
↑ 43.1%
Net Income
$-57591000
↓ 179.7%
Shareholders' Equity
$106.6M
↑ 295.1%
Total Liabilities
$10.5M
↑ 95.6%
Total Assets
$117.2M
↑ 51.2%
Cash & Equivalents
$47.1M
↓ 23.7%
Operating Cash Flow
$-54172000.00
↓ 199.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| EFFECT | 4/3/2026 | View on SEC |
| 424B5 | 4/3/2026 | View on SEC |
| 8-K | 3/24/2026 | View on SEC |
| S-8 | 3/24/2026 | View on SEC |
| S-3 | 3/23/2026 | View on SEC |
| 10-K | 3/23/2026 | View on SEC |
| 8-K | 3/23/2026 | View on SEC |
| 8-K | 2/27/2026 | View on SEC |
| 8-K | 2/12/2026 | View on SEC |
| 4 | 2/11/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AARD |
| Company Name | Aardvark Therapeutics, Inc. |
| CIK | 1774857 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (858) 225-7696 |